Nicola Maurea

List of Publications by Year in Descending Order

53 papers	1,179 citations	23 h-index	33 g-index
57 ext. papers	1,482 ext. citations	5 avg, IF	4.04 L-index

#	Paper	IF	Citations
53	Biocompatible, photo-responsive layer-by-layer polymer nanocapsules with an oil core: and study.. *Journal of the Royal Society Interface*, **2022**, 19, 20210800	4.1	0
52	The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. *Antioxidants*, **2022**, 11, 1090	7.1	0
51	Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 677544	5.4	1
50	Polydatin Reduces Cardiotoxicity and Enhances the Anticancer Effects of Sunitinib by Decreasing Pro-Oxidative Stress, Pro-Inflammatory Cytokines, and NLRP3 Inflammasome Expression. *Frontiers in Oncology*, **2021**, 11, 680758	5.3	5
49	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. *Journal of Cardiovascular Pharmacology*, **2021**, 78, e20-e29	3.1	6
48	The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. *Cardiovascular Diabetology*, **2021**, 20, 150	8.7	27
47	Resveratrol in Cancer Patients: From Bench to Bedside. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	32
46	Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab. *International Journal of Nanomedicine*, **2020**, 15, 4859-4876	7.3	12
45	Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. *Antioxidants*, **2020**, 9,	7.1	14
44	SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients. *Cancers*, **2020**, 12,	6.6	13
43	NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	14
42	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. *Journal of Personalized Medicine*, **2020**, 10,	3.6	14
41	Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with -mutated metastatic colorectal cancer: the REVOLUTION study protocol. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920929589	5.4	4
40	Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells. *Phytotherapy Research*, **2019**, 33, 1670-1682	6.7	8
39	Management of QT Prolongation Induced by Anticancer Drugs. *Current Clinical Pathology*, **2019**, 123-132	0.1	
38	Oil Core-PEG Shell Nanocarriers for In Vivo MRI Imaging. *Advanced Healthcare Materials*, **2019**, 8, e1801313	13.1	14
37	Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. *PLoS ONE*, **2019**, 14, e0210330	3.7	3

36	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. *Cancer Treatment Reviews*, **2018**, 63, 135-143	14.4	34
35	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. *Frontiers in Physiology*, **2018**, 9, 38	4.6	24
34	Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. *OncoTargets and Therapy*, **2018**, 11, 2241-2250	4.4	23
33	Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity. *Nutrients*, **2018**, 10,	6.7	42
32	Intracardiac metastasis originated from chondrosarcoma. *Journal of Cardiovascular Medicine*, **2017**, 18, 385-388	1.9	3
31	ANMCO/AIOM/AICO Consensus Document on clinical and management pathways of cardio-oncology: executive summary. *European Heart Journal Supplements*, **2017**, 19, D370-D379	1.5	15
30	Enhanced Drug Delivery into Cell Cytosol via Glycoprotein H-Derived Peptide Conjugated Nanoemulsions. *ACS Nano*, **2017**, 11, 9802-9813	16.7	28
29	Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. *Human Vaccines and Immunotherapeutics*, **2016**, 12, 1124-31	4.4	36
28	Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. *OncoTargets and Therapy*, **2016**, 9, 6785-6794	4.4	16
27	Pathophysiology of anthracycline cardiotoxicity. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S3-S11	1.9	25
26	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S84-92	1.9	39
25	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S93-S104	1.9	31
24	Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S19-26	1.9	37
23	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. *European Journal of Heart Failure*, **2014**, 16, 358-66	12.3	61
22	Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. *Protein Engineering, Design and Selection*, **2014**, 27, 83-8	1.9	13
21	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). *BMC Cancer*, **2014**, 14, 875	4.8	27
20	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. *Diabetology and Metabolic Syndrome*, **2014**, 6, 105	5.6	15
19	Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer. *Journal of Cardiovascular Medicine*, **2014**, 15, 141-6	1.9	21

18	Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience. *Journal of Experimental and Clinical Cancer Research*, **2013**, 32, 14	12.8	25
17	Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. *Trials*, **2013**, 14, 273	2.8	19
16	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. *Future Oncology*, **2013**, 9, 127-33	3.6	1
15	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. *European Journal of Heart Failure*, **2013**, 15, 482-9	12.3	52
14	Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. *Journal of Cardiac Failure*, **2012**, 18, 113-9	3.3	78
13	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. *European Journal of Heart Failure*, **2012**, 14, 130-7	12.3	69
12	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. *Breast Cancer Research and Treatment*, **2012**, 133, 511-21	4.4	38
11	Administration of angiotensin-converting enzyme inhibitors and -blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?. *Oncologist*, **2012**, 17, 917-24	5.7	40
10	Approccio cardiologico al paziente sottoposto a trattamento antitumorale. Documento primo. *Journal of Cardiovascular Echography*, **2011**, 21, 32-41	0.6	
9	Le alterazioni elettrocardiografiche espressione di cardiotossicit*Journal of Cardiovascular Echography*, **2011**, 21, 55-59	0.6	
8	Early identification of left ventricular dysfunction induced by trastuzumab. *Journal of the American College of Cardiology*, **2011**, 58, 2698-9; author reply 2699-700	15.1	3
7	Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. *European Heart Journal Cardiovascular Imaging*, **2011**, 12, 636	4.1	1
6	Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. *Cancer Biology and Therapy*, **2010**, 10, 1240-3	4.6	66
5	Circadian rhythms, adrenergic hormones and trafficking of hematopoietic stem cells. *Expert Opinion on Therapeutic Targets*, **2010**, 14, 567-75	6.4	15
4	Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. *Journal of Cardiovascular Medicine*, **2010**, 11, 861-8	1.9	36
3	Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial. *BMC Cancer*, **2007**, 7, 50	4.8	22
2	Effects of histamine on coronary hemodynamics in humans: role of H1 and H2 receptors. *Journal of the American College of Cardiology*, **1987**, 10, 1207-13	15.1	44
1	Direct coronary vasodilator effects of intracoronary histamine administration in humans. *Journal of Cardiovascular Pharmacology*, **1986**, 8, 933-9	3.1	7